When and where will MindMaze Therapeutics hold its 2026 Annual General Meeting?

MindMaze Therapeutics will hold its 2026 AGM on June 25, 2026, at 11:00 a.m. CEST in Geneva, Switzerland.

What board appointments will MindMaze Therapeutics propose at the 2026 AGM?

MindMaze Therapeutics will propose the re-election of the current Board members and the election of Brad Hollinger and Zach Henderson as new Board members. Brad Hollinger is identified as Founder, Chairman and Chief Executive Officer of Vibra Healthcare, while Zach Henderson is identified as Chief Executive Officer of MindMaze Therapeutics.

What annual report and financial statements will MindMaze Therapeutics shareholders vote on?

Shareholders will be asked to approve MindMaze Therapeutics’ 2025 Annual Report and financial statements at the 2026 AGM.

Which committee and oversight appointments are on the MindMaze Therapeutics AGM agenda?

The agenda includes elections for the members of the Nomination and Compensation Committee, the Independent Proxy and the statutory auditors.

Will MindMaze Therapeutics shareholders vote on executive and board compensation at the 2026 AGM?

Yes. MindMaze Therapeutics shareholders will be asked to vote on the compensation of the Board of Directors and the Executive Committee.

What share capital proposal will MindMaze Therapeutics put to shareholders?

MindMaze Therapeutics shareholders will be asked to approve an increase in the Company’s conditional share capital.

Where can investors find the MindMaze Therapeutics AGM invitation and proposal details?

Further details on the proposals and the AGM invitation are available on the MindMaze Therapeutics website.

What does MindMaze Therapeutics do?

MindMaze Therapeutics describes itself as a global leader in scalable, precision neurotherapeutics. It integrates advanced software, proprietary sensors and AI-driven data analytics to provide care from the acute hospital phase through outpatient treatment and home-based therapy.

Which conditions do MindMaze Therapeutics’ products address?

MindMaze Therapeutics says its FDA-cleared and CE-marked products are designed to offer scalable, reimbursable solutions for stroke, Parkinson’s disease and other neurological disorders.

Where do MindMaze Therapeutics shares trade and what is the ticker symbol?

MindMaze Therapeutics shares trade on SIX under the ticker symbol MMTX.

Home
News Intelligence
MindMaze Therapeutics Holding SA
MindMaze Therapeutics Publishes Invitation for 2026 Annual General Meeting

Back to all MindMaze Therapeutics Holding SA press releases

MindMaze Therapeutics Holding SA

OTCQB:MMTZF
SIX:MMTX

MindMaze Therapeutics Publishes Invitation for 2026 Annual General Meeting

Published Wednesday, 03 June 2026, 04:45 AM

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

At a glance

Company: MindMaze Therapeutics Holding SA
Listings: OTCQB:MMTZF, SIX:MMTX
Announcement type: Corporate update
Published: Wednesday, 03 June 2026, 04:45 AM
Source announcement: eqs-news.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

MindMaze Therapeutics Holding SA (SIX: MMTX) published an invitation to its annual general meeting.

The 2026 AGM is scheduled for June 25, 2026, at 11:00 a.m. CEST in Geneva, Switzerland.
The Board proposes re-electing current members and electing Brad Hollinger and Zach Henderson as directors.
Votes cover the 2025 Annual Report, financial statements, committee, proxy and auditor elections.

Shareholders will vote on Board and Executive Committee compensation and a conditional share-capital increase.

Investor FAQs

MindMaze Therapeutics announced that it had published the invitation to its 2026 Annual General Meeting (AGM). The meeting is scheduled to take place in Geneva, Switzerland.

Source announcement

Company: MindMaze Therapeutics Holding SA
Title: MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
Published: Wednesday, 03 June 2026, 04:45 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…